Antidepressants versus placebo in major depression: An overview

World Psychiatry

Volumn 14, Issue 3, 2015, Pages 294-300

  Khan, Arif ^a,b   Brown, Walter A ^c  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

antidepressants; clinical trials; drug development regulators; expectation bias; Major depression; placebo

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; IMIPRAMINE; PHENELZINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VILAZODONE;

CLINICAL GLOBAL IMPRESSION SCALE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DSM-III; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MEDICAL DECISION MAKING; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

EID: 84942517093     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20241     Document Type: Review

References (45)

1. U.S. Department of Health and Human Services. Depression in primary care: treatment of major depression. Vol. 2, Clinical Practice Guideline No. 5. Washington: U.S. Government Printing Office, 1993.
2. Kuhn R., The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 1958; 115: 459-64.
3. Clinical Psychiatry Committee. Clinical trial of the treatment of depressive illness: report to the Medical Research Council. BMJ 1965; 1: 881-6.
4. Hamilton M., A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
5. Klerman GL, Cole JO., Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev 1965; 17: 101-41.
6. Brown WA, Khan A., Which depressed patients should receive antidepressants? CNS Drugs 1994; 1: 341-7.
7. Khan A, Warner H, Brown WA., Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the FDA database. Arch Gen Psychiatry 2000; 57: 311-7.
8. Walsh BT, Seidman SN, Sysko R, et al., Placebo response in studies of depression: variable, substantial, and growing. JAMA 2002; 287: 1840-7.
9. Rush AJ, Fava M, Wisniewski SR., Sequenced Treatment Alternatives to Relieve Depression (STARD): rationale and design. Control Clin Trials 2004; 25: 119-42.
10. Blier P., Do antidepressants really work? J Psychiatry Neurosci 2008; 33: 89-90.
11. Begley S., Why antidepressants are no better than placebos. Newsweek, January 29, 2010.
12. DeAngelis CD, Fontanarosa PB., Impugning the integrity of medical science: the adverse effects of industry influence. JAMA 2008; 299: 1833-5.
13. Khan A, Faucett J, Lichtenberg P, et al., A systematic review of comparative efficacy of treatments and controls for depression. PLoS One 2012; 7: e41778.
14. Sinyor M, Levitt AJ, Cheung AH, et al., Does inclusion of a placebo arm influence active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 2010; 71: 270-9.
15. Brown WA., The placebo effect in clinical practice. Oxford: Oxford University Press, 2013.
16. Frank JD, Frank JB., Persuasion and healing: a comparative study of psychotherapy, 3rd ed. Baltimore: Johns Hopkins University Press, 1991.
17. Patel SM, Statson WB, Legedza A, et al., The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005; 17: 332-40.
18. Sutherland LR, May GR, Shaffer EA., Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 540-9.
19. Preston RA, Materson BJ, Reda DJ, et al., Placebo-associated blood pressure response and adverse effects in the treatment of hypertension. Arch Int Med 2000; 160: 1449-54.
20. Joyce DP., The placebo effect in asthma drug therapy trials: a meta-analysis. J Asthma 2000; 37: 303-18.
21. Mosely JB, O'Malley K, Petersen NJ, et al., A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347: 81-8.
22. Ondo WG, Sethi KD, Kricorian G., Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms. Clin Neuropharmacol 2007; 30: 295-300.
23. Pagnin D, de Quiroz V, Pini S, et al., Efficacy of ECT in depression. J ECT 2004; 20: 13-20.
24. Rush AJ, Marangell LB, Sackeim HA., Vagus nerve stimulation for treatment resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58: 347-54.
25. Quitkin FM, Rabkin JG, Ross D, et al., Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry 1984; 41: 782-6.
26. Khan A, Redding N, Brown WA., The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res 2008; 42: 791-6.
27. Mayberg HS, Silva AJ, Brannan SK, et al., The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-37.
28. Benedetti F, Mayberg HS, Wager TD, et al., Neurobiological mechanisms of the placebo effect. J Neurosci 2005; 25: 10390-402.
29. Burt CG, Gordon WF, Holt NF, et al., Amitriptyline in depressive states: a controlled trial. Br J Psychiatry 1962; 108: 711-30.
30. Montgomery SA, Asberg M., A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
31. Khan A, Cohen S, Dager S., Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. J Affect Disord 1989; 17: 33-8.
32. Geddes JR, Carney SM, Davies C., Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 653-61.
33. Rutherford BR, Roose SP., A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013; 170: 723-33.
34. Khan A, Leventhal RM, Khan S, et al., Severity of depression and response to antidepressants and placebo: an analysis of the FDA database. J Clin Psychopharmacol 2002; 22: 40-5.
35. Khan A, Brodhead AE, Kolts RL, et al., Severity of depressive symptoms and response to antidepressants and placebo in antidepressant clinical trials. J Psychiatr Res 2005; 39: 145-50.
36. Khan A, Schwartz K, Kolts RL, et al., Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol Psychiatry 2007; 62: 65-71.
37. Khan A, Bhat A, Kolts R, et al., Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades. CNS Neurosci Ther 2010; 16: 217-26.
38. Mundt JF, Greist JH, Jefferson JW, et al., Is it easier to find what you are looking for if you think you know what it looks like? J Clin Psychopharmacol 2007; 27: 121-5.
39. Khan A, Faucett J, Brown W., Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews. J Psychiatr Res 2014; 51: 88-92.
40. Khan A, Faucett J, Brown W., Magnitude of change with antidepressants and placebo in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional semi-structured interviews. Psychopharmacology 2014; 231: 4301-7.
41. Gibertini M, Nations KR, Whitaker JA., Obtained effect size as a function of sample size in approved antidepressants: a real-world illustration in support of better trial design. Int Clin Psychopharmacol 2012; 27: 100-6.
42. Khan A., Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs 2009; 18: 1-12.
43. Patel HC, Hayward C, Ozdemir BA, et al., Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials. Hypertension 2015; 65: 401-6.
44. Schilling JP, Khan SRF, Khan A., Outcome measures and serious asthma exacerbation in clinical trials of asthma controller medications. Ann Allergy Asthma Immunol 2012; 108: 448-53.
45. Shojania KG, Sumant RR, McDonald KM, et al., Effects of quality improvement strategies for type II diabetes on glycemic control: a meta-regression analysis. JAMA 2006; 296: 427-40.